Retatrutide
Retatrutide is a synthetic investigational peptide that acts at three receptors (GIP, GLP-1 and glucagon), studied in phase 2 and phase 3 clinical trials. Atlas RND supplies it as a lyophilized research peptide for laboratory research use only.
Read the 9 published studiesLast updated
For laboratory research use only. The literature below is provided for educational reference by qualified researchers. It is not medical advice, and nothing on this page is a claim about Retatrutide. Not for human or veterinary use.
Published research on Retatrutide
Peer-reviewed studies grouped by what they investigated, with human clinical trials first, then reviews, then laboratory work. Each links to the original paper.
Obesity clinical trials 3 studies
Study title: Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.
Study title: Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Study title: Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.
Type 2 diabetes clinical trials 3 studies
Study title: Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
Study title: Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Study title: Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
Liver research 1 study
Study title: Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Knee osteoarthritis and sleep apnea trials (design) 1 study
Study title: Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
Discovery and pharmacology 1 study
Study title: LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Important research notice. These studies are posted for research reference only. Titles are reproduced exactly as their authors published them and describe what those researchers investigated; they are not claims by Atlas RND about any product. Not for human consumption. All literature is provided for educational reference only and must not be interpreted as medical advice or product claims. Studies of a compound by other groups are not studies of Atlas RND material. By purchasing from Atlas RND you confirm you are a qualified researcher and will use products in accordance with all applicable laws and regulations. Back to the research library →
Molecular profile
Quality and lot testing
Related compounds
NAD+ · Tirzepatide · Wolverine Stack · Glow · BPC-157 · TB-500 · GHK-Cu · DSIP · MOTS-C · Retatrutide product page